~~<i id='C79DFC6D75'><strike id='C79DFC6D75'><tt id='C79DFC6D75'><pre id='C79DFC6D75'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-09-06 06:45:53 Page View：255

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Telehealth startups are trying to fill the menopause care vacuum
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Biden jokes that Republicans may impeach him because inflation is starting to cool down

PresidentJoeBidengreetsguestsafterspeakingatAuburnManufacturingInc.,inAuburn,Maine,Friday,July28,202

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

After a decade, new Gardasil ad campaign gets it (mostly) right

Screengrabviaversedhpv.comWhileclickingthroughSnapchattheotherday,anadforMerck’snewVersedcampaignfor